Top Story

High dose peanut patch shows promise for peanut sensitivity

November 14, 2017

Read the Perspective from Matthew Greenhawt, MD

Patients with peanut sensitivity who wore a 250-µg epicutaneous immunotherapy-based peanut patch had a significant treatment response compared to patients wearing patches with smaller doses or placebo, according to phase 2b trial findings recently published in JAMA.

“Numerous single-center studies [on immunotherapies] have been published; although they have demonstrated induction of varying degrees of desensitization, there is concern about significant risk of severe treatment-associated adverse reactions,” Hugh A. Sampson, MD, department of pediatrics, Icahn School of Medicine at Mount Sinai, New York City, and colleagues wrote. “Moreover, only a minority of treated patients achieve any measure of longer-term tolerance.”

Meeting News

Outpatient program appears safe, effective in patients allergic to chemotherapy

November 8, 2017
BOSTON — The implementation of an outpatient chemotherapy desensitization program appeared safe and significantly reduced the mean time from arrival to…
Meeting News

Many food allergic adults develop a new food allergy in adulthood

November 8, 2017
BOSTON - Approximately half of 40,447 food-allergic adults reported one or more adult-onset food allergies, according to findings presented at the American College of…
Meeting News

Antibiotic allergies less prevalent than once believed

November 7, 2017
BOSTON — An overwhelming majority of individuals who believe they are allergic to cephalosporins and who are referred to seek confirmatory testing, are ultimately…
More Headlines »